European Journal of Epidemiology

, Volume 27, Issue 8, pp 593–603 | Cite as

Use of glucosamine and chondroitin in relation to mortality

  • Griffith A. BellEmail author
  • Elizabeth D. Kantor
  • Johanna W. Lampe
  • Danny D. Shen
  • Emily White


Glucosamine and chondroitin are products commonly used by older adults in the US and Europe. There is limited evidence that they have anti-inflammatory properties, which could provide risk reduction of several diseases. However, data on their long-term health effects is lacking. To evaluate whether use of glucosamine and chondroitin are associated with cause-specific and total mortality. Participants (n = 77,510) were members of a cohort study of Washington State (US) residents aged 50–76 years who entered the cohort in 2000–2002 by completing a baseline questionnaire that included questions on glucosamine and chondroitin use. Participants were followed for mortality through 2008 (n = 5,362 deaths). Hazard ratios (HR) for death adjusted for multiple covariates were estimated using Cox models. Current (baseline) glucosamine and chondroitin use were associated with a decreased risk of total mortality compared to never use. The adjusted HR associated with current use of glucosamine (with or without chondroitin) was 0.82 (95 % CI 0.75–0.90) and 0.86 (95 % CI 0.78–0.96) for chondroitin (included in two-thirds of glucosamine supplements). Current use of glucosamine was associated with a significant decreased risk of death from cancer (HR 0.87 95 % CI 0.76–0.98) and with a large risk reduction for death from respiratory diseases (HR 0.59 95 % CI 0.41–0.83). Use of glucosamine with or without chondroitin was associated with reduced total mortality and with reductions of several broad causes of death. Although bias cannot be ruled out, these results suggest that glucosamine may provide some mortality benefit.


Glucosamine Chondroitin Supplements Mortality Cohort Cancer 



This work was supported by grants R01-CA142545, R25-CA94880, and K05-CA154337 from the National Cancer Institute (US).


  1. 1.
    Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA, J Am Med Assoc. 2008;300(24):2867–78.CrossRefGoogle Scholar
  2. 2.
    Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.PubMedCrossRefGoogle Scholar
  3. 3.
    Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Wandel S, Juni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilkens P, Scheel IB, Grundnes O, Hellum C, Storheim K. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA. 2010;304(1):45–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Herrero-Beaumont G, Ivorra JAR, Trabado MDC, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms—a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthr Rheum. 2007;56(2):555–67.CrossRefGoogle Scholar
  7. 7.
    Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthr Cartil. 2008;16(Suppl 3):S14–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Largo R, Alvarez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthr Cartil. 2003;11(4):290–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Chan PS, Caron JP, Rosa GJ, Orth MW. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthr Cartil. 2005;13(5):387–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Kantor ED LJ, Vaughan TL, Peters U, Rehm CD, White E. Association of specialty supplement use with C-reactive protein. Am J Epidemiol 2012. (in press.).Google Scholar
  11. 11.
    Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109(21 Suppl 1):II2–10.Google Scholar
  14. 14.
    Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34(10):2518–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Pocobelli G, Kristal AR, Patterson RE, et al. Total mortality risk in relation to use of less-common dietary supplements. Am J Clin Nutr. 2010;91(6):1791–800.PubMedCrossRefGoogle Scholar
  16. 16.
    Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98(6):746–50.PubMedCrossRefGoogle Scholar
  18. 18.
    White E, Patterson RE, Kristal AR, et al. VITamins And Lifestyle cohort study: study design and characteristics of supplement users. Am J Epidemiol. 2004;159(1):83–93.PubMedCrossRefGoogle Scholar
  19. 19.
    Onoue S, Misaka S, Kawabata Y, Yamada S. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin Drug Deliv. 2009;6(8):793–811.PubMedCrossRefGoogle Scholar
  20. 20.
    Littman AJ, White E, Kristal AR, Patterson RE, Satia-Abouta J, Potter JD. Assessment of a one-page questionnaire on long-term recreational physical activity. Epidemiology. 2004;15(1):105–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the women’s health initiative food frequency questionnaire. Ann Epidemiol. 1999;9(3):178–87.PubMedCrossRefGoogle Scholar
  22. 22.
    U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans. Washington, DC: US GPO; 2005.Google Scholar
  23. 23.
    Organization WH. International statistical classification of diseases and related health problems, 10th revision. Version for 2007. Geneva: World Health Organization.Google Scholar
  24. 24.
    Brasky TM, Lampe JW, Slatore CG, White E. Use of glucosamine and chondroitin and lung cancer risk in the VITamins and lifestyle (VITAL) cohort. Cancer Causes Control. 2011;22(9):1333–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009;18(5):1419–28.PubMedCrossRefGoogle Scholar
  26. 26.
    Brasky TM, Lampe JW, Potter JD, Patterson RE, White E. Specialty supplements and breast cancer risk in the VITamins and lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1696–708.PubMedCrossRefGoogle Scholar
  27. 27.
    Walter RB, Brasky TM, Milano F, White E. Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins and lifestyle (VITAL) study. Cancer Epidemiol Biomarkers Prev. 2011;20(10):2298–308.PubMedCrossRefGoogle Scholar
  28. 28.
    Duan W, Paka L, Pillarisetti S. Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis. Cardiovasc Diabetol. 2005;4:16.PubMedCrossRefGoogle Scholar
  29. 29.
    Herrero-Beaumont G, Marcos ME, Sanchez-Pernaute O, et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol. 2008;154(4):843–51.PubMedCrossRefGoogle Scholar
  30. 30.
    Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol. 2007;293(3):H1391–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Xing D, Feng W, Not LG, et al. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol. 2008;295(1):H335–42.PubMedCrossRefGoogle Scholar
  32. 32.
    Zou L, Yang S, Champattanachai V, et al. Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling. Am J Physiol Heart Circ Physiol. 2009;296(2):H515–23.PubMedCrossRefGoogle Scholar
  33. 33.
    Lin PC, Jones SO, McGlasson DL. Effects of glucosamine and Celadrin on platelet function. Clin Lab Sci. 2010;23(1):32–6.PubMedGoogle Scholar
  34. 34.
    Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst. 2007;99(11):881–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24(5B):3177–84.Google Scholar
  36. 36.
    Molfino NA, Jeffery PK. Chronic obstructive pulmonary disease: histopathology, inflammation and potential therapies. Pulm Pharmacol Ther. 2007;20(5):462–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development. Lancet. 2011;378(9795):1027–37.PubMedCrossRefGoogle Scholar
  38. 38.
    Xu CX, Jin H, Chung YS, et al. Chondroitin sulfate extracted from the Styela clava tunic suppresses TNF-alpha-induced expression of inflammatory factors, VCAM-1 and iNOS by blocking Akt/NF-kappaB signal in JB6 cells. Cancer Lett. 2008;264(1):93–100.PubMedCrossRefGoogle Scholar
  39. 39.
    Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 2005;26(6):318–25.PubMedCrossRefGoogle Scholar
  40. 40.
    Chou MM, Vergnolle N, McDougall JJ, et al. Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood). 2005;230(4):255–62.Google Scholar
  41. 41.
    Sakai S, Sugawara T, Kishi T, Yanagimoto K, Hirata T. Effect of glucosamine and related compounds on the degranulation of mast cells and ear swelling induced by dinitrofluorobenzene in mice. Life Sci. 2010;86(9–10):337–43.PubMedCrossRefGoogle Scholar
  42. 42.
    Xu CX, Jin H, Chung YS, et al. Chondroitin sulfate extracted from ascidian tunic inhibits phorbol ester-induced expression of Inflammatory factors VCAM-1 and COX-2 by blocking NF-kappaB activation in mouse skin. J Agric Food Chem. 2008;56(20):9667–75.PubMedCrossRefGoogle Scholar
  43. 43.
    Chan PS, Caron JP, Orth MW. Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate. J Rheumatol. 2006;33(7):1329–40.PubMedGoogle Scholar
  44. 44.
    Nakamura H, Nishioka K. Effects of glucosamine/chondroitin supplement on osteoarthritis: involvement of PGE2 and YKL-40. Jpn J Rheum Joint Surg. 2002;21(2):175–84.Google Scholar
  45. 45.
    Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T, Kawahara T. Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 2007;27(3):213–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–99.PubMedCrossRefGoogle Scholar
  47. 47.
    Solomon SD, Wittes J, Finn PV, et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation. 2008;117(16):2104–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Griffith A. Bell
    • 1
    • 2
    Email author
  • Elizabeth D. Kantor
    • 1
    • 2
  • Johanna W. Lampe
    • 1
    • 3
  • Danny D. Shen
    • 4
    • 5
  • Emily White
    • 1
    • 2
  1. 1.Cancer Prevention ProgramThe Fred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  3. 3.Department of Epidemiology and Interdisciplinary Program in Nutritional SciencesUniversity of WashingtonSeattleUSA
  4. 4.Department of Pharmacy and Pharmaceutics, School of PharmacyUniversity of WashingtonSeattleUSA
  5. 5.Clinical Research DivisionThe Fred Hutchinson Cancer Research CenterSeattleUSA

Personalised recommendations